Kidswell Bio

January 26, 2022

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Announcement of business alliance agreement with Metcela Inc. for the regenerative

medicine business

Tokyo, January 26, 2022 - Kidswell Bio Corporation (KWB) executed a business alliance agreement

with Metcela Inc. (Metcela) on January 19, 2022 for accelerating the regenerative medicine business

of KWB and Metcela by combining management resources, knowledge and technologies in the

regenerative medicine field.

Metcela has been developing "MTC001", a combination product of Metcela's proprietary fibroblast-

based autologous cell therapy and a delivery catheter system for chronic heart failure for which there

is no radical treatment. Metcela has established a comprehensive system of fundamental research,

manufacturing process development, clinical trial product manufacturing, and clinical development,

and further accelerate incorporating new pipelines from outside.

By concluding this business alliance agreement, KWB expects starting clinical trials of SHED (Stem

cell from Human Exfoliated Deciduous teeth) and expansion of SHED indications with Metcela's

research and development knowledge. KWB will provide SHEDs for the development of new pipelines

for Metcela and continue further discussions on supporting the expansion of Metcela's fibroblast

business with KWB's know-how of establishment of SHED master cell bank.

The impact on the business results for the fiscal year ending March 2022 is expected to be minimal.

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable

and rare diseases on which GTS has also been focusing for R&D. We would like to contribute to

children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise

and children's potential vital force such as SHED and CSC, we envision creating new pharmaceuticals

and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation